Blocking histone deacetylase activity as a novel target for epithelial barrier defects in patients with allergic rhinitis

• Published in: Journal of allergy and clinical immunology Vol. 144; no. 5; pp. 1242 - 1253.e7
• Main Authors: Steelant, Brecht, Wawrzyniak, Paulina, Martens, Katleen, Jonckheere, Anne-Charlotte, Pugin, Benoit, Schrijvers, Rik, Bullens, Dominique M., Vanoirbeek, Jeroen A., Krawczyk, Krzysztof, Dreher, Anita, Akdis, Cezmi A., Hellings, Peter W.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.11.2019; Elsevier Limited
• Subjects: Allergic rhinitis; Asthma; Defects; Dextran; DNA methylation; epigenetic changes; Epigenetics; Epithelial cells; Fluorescein isothiocyanate; Gene expression; Genes; Histone deacetylase; Hyperreactivity; Hypersensitivity; Immunofluorescence; Inflammation; Membrane permeability; Mucosa; Permeability; primary nasal epithelial cells; Proteins; Respiratory tract diseases; Tight junctions; Belgium; Germany; TER; TSLP; DAPI; FP; histone deacetylase; BAL; HDM; AR; ZO-1; Allergic rhinitis; epigenetic changes; tight junctions; primary nasal epithelial cells; ALI; HDAC
• ISSN: 0091-6749; 1097-6825; 1097-6825
• DOI: 10.1016/j.jaci.2019.04.027

A defective epithelial barrier is found in patients with allergic rhinitis (AR) and asthma; however, the underlying mechanisms remain poorly understood. Histone deacetylase (HDAC) activity has been identified as a crucial driver of allergic inflammation and tight junction dysfunction. We investigated whether HDAC activity has been altered in patients with AR and in a mouse model of house dust mite (HDM)–induced allergic asthma and whether it contributed to epithelial barrier dysfunction. Primary nasal epithelial cells of control subjects and patients with AR were cultured at the air-liquid interface to study transepithelial electrical resistance and paracellular flux of fluorescein isothiocyanate–dextran (4 kDa) together with mRNA expression and immunofluorescence staining of tight junctions. Air-liquid interface cultures were stimulated with different concentrations of JNJ-26481585, a broad-spectrum HDAC inhibitor. In vivo the effect of JNJ-26481585 on mucosal permeability and tight junction function was evaluated in a mouse model of HDM-induced allergic airway inflammation. General HDAC activity was greater in nasal epithelial cells of patients with AR and correlated inversely with epithelial integrity. Treatment of nasal epithelial cells with JNJ-26481585 restored epithelial integrity by promoting tight junction expression and protein reorganization. HDM-sensitized mice were treated with JNJ-26481585 to demonstrate the in vivo role of HDACs. Treated mice did not have allergic airway inflammation and had no bronchial hyperreactivity. Moreover, JNJ-26481585 treatment restored nasal mucosal function by promoting tight junction expression. Our findings identify increased HDAC activity as a potential tissue-injury mechanism responsible for dysregulated epithelial cell repair, leading to defective epithelial barriers in AR. Blocking HDAC activity is a promising novel target for therapeutic intervention in patients with airway diseases. [Display omitted]